Trial Profile
A Randomized, Placebo-controlled Trial to Evaluate the Optimal Dose of MV-LASV, a New Vaccine Against LASSA Virus Infection, Regarding Safety, Tolerability & Immunogenicity in Healthy Volunteers Consisting of an Unblinded Dose Escalation & an Observer-blinded Treatment Phase
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Lassa fever vaccine (Primary)
- Indications Lassa fever
- Focus Adverse reactions; First in man
- Sponsors Themis Bioscience
- 26 Jan 2021 Status changed from active, no longer recruiting to completed.
- 01 Dec 2020 Planned End Date changed from 1 Feb 2021 to 30 Apr 2021.
- 13 Aug 2020 Planned End Date changed from 1 Dec 2020 to 1 Feb 2021.